RHY 2.04% 10.0¢ rhythm biosciences limited

Ann: RHY Advances Platform Expansion with Other Cancers, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,448 Posts.
    lightbulb Created with Sketch. 2798
    Yes, encouraging update. They continue to make progress but no money ball yet.

    I think it interesting that the statement refers to "pan-cancerous" as I am fairly sure that in a recent interview Glenn put the kibosh on any talk like that, insisting that each of the cancers will be addressed individually. I cannot track the interview down so maybe I have my wires crossed. But at the time I thought he was mindful of the bad connotations from the recent Theranos trials which showed that Elizabeth Holmes had rigged results from her pan-disease testing system.

    I hope Glenn and Otto take it a step at a time as even if they can bring just one of the other cancers into scope that would be a massive victory. So, one at a time. Having commercialised tests for colon cancer and just one of the other cancers would make Rhythm a superstar. No need to get too greedy and over-promise.
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.